Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
ConditionLocal Advanced or Metastatic NSCLC
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSun Yat-sen University
About this trial
This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC
Eligibility criteria
Qualifiers
Neutrophil count≥1.5×109/L,
Platelet count≥90×109/L,
Hemoglobin≥90g/L
Serum creatinine≤1.5×upper limit of normal (ULN), creatinine clearance≥50 mL/min (Cockcroft-Gault formula)
Disqualifiers
NYHA (New York Heart Association) Class 3 and 4 congestive heart failure
Arrhythmia requiring therapeutic intervention
Thrombotic or embolic event within the past 6 months, e.g., cerebrovascular accident (including transient ischemic attack), and pulmonary embolism
LVEF<50%
Trial design
Treatments tested in this trial
- Garsorasib, Benmelstobart, Anlotinib
- Benmelstobart, Anlotinib
- Garsorasib, Cetuximab Beta Injection
Treatment groups
69 Participants
are divided into 3 treatment groupsSponsors and collaborators
Sun Yat-sen University
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborator
Source ClinicalTrials.gov